FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3207591866> ?p ?o ?g. }

• W3207591866 endingPage "3028" @default.
• W3207591866 startingPage "3016" @default.
• W3207591866 abstract "To report post hoc results on how adjustments to baseline antiseizure medications (ASMs) in a subset of study sites (10 US sites) from a long-term, open-label phase 3 study of adjunctive cenobamate affected tolerability, efficacy, and retention.Patients with uncontrolled focal seizures taking stable doses of one to three ASMs were administered increasing doses of cenobamate (12.5, 25, 50, 100, 150, 200 mg/day) over 12 weeks at 2-week intervals (target dose = 200 mg/day). Further increases to 400 mg/day by 50 mg/day biweekly increments were allowed during maintenance phase. Dose adjustments of cenobamate and concomitant ASMs were allowed. Data were assessed until last visit, at data cut-off, on or after September 1, 2019.A total of 240 patients meeting eligibility criteria were assessed (median [max] exposure 30.2 [43.0] months), with 177 patients continuing cenobamate at data cut-off. Most common baseline concomitant ASMs were lacosamide, levetiracetam, lamotrigine, zonisamide, and clobazam. For most baseline concomitant ASMs, ~70% of patients taking that ASM were continuing cenobamate at data cut-off. Patients continuing cenobamate had greater mean ASM dose reductions and percent dose changes from baseline vs those who discontinued. Of patients continuing cenobamate, 24.6% discontinued one or more concomitant ASMs completely. Dose decreases for all concomitant ASMs generally occurred during titration or early maintenance phases and were mostly due to central nervous system (CNS)-related adverse events such as somnolence, dizziness, unsteady gait, and fatigue. Responder rates from ≥50% through 100% for patients continuing cenobamate were generally similar regardless of concomitant ASMs (of those most commonly taken), with ~81% being ≥50% responders and ~12% achieving 100% seizure reduction in the maintenance phase, which lasted up to 40.2 (median = 29.5) months.Concomitant ASM dose reductions were associated with more patients remaining on cenobamate. This is likely due to efficacy and improved tolerability, with overall reduced concomitant drug burden in patients with uncontrolled seizures despite taking one to three baseline concomitant ASMs." @default.
• W3207591866 created "2021-10-25" @default.
• W3207591866 creator A5000233437 @default.
• W3207591866 creator A5004620817 @default.
• W3207591866 creator A5012220015 @default.
• W3207591866 creator A5012722318 @default.
• W3207591866 creator A5016663277 @default.
• W3207591866 creator A5025122018 @default.
• W3207591866 creator A5030901765 @default.
• W3207591866 creator A5052410565 @default.
• W3207591866 creator A5062520786 @default.
• W3207591866 creator A5085356343 @default.
• W3207591866 date "2021-10-11" @default.
• W3207591866 modified "2023-10-14" @default.
• W3207591866 title "Post hoc analysis of a phase 3, multicenter, open‐label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications" @default.
• W3207591866 cites W1522349457 @default.
• W3207591866 cites W1873975405 @default.
• W3207591866 cites W1976354860 @default.
• W3207591866 cites W1986601214 @default.
• W3207591866 cites W2014466194 @default.
• W3207591866 cites W2024087203 @default.
• W3207591866 cites W2025114653 @default.
• W3207591866 cites W2033614870 @default.
• W3207591866 cites W2038159150 @default.
• W3207591866 cites W2069987842 @default.
• W3207591866 cites W2091074713 @default.
• W3207591866 cites W2093148987 @default.
• W3207591866 cites W2099478180 @default.
• W3207591866 cites W2121613199 @default.
• W3207591866 cites W2147917303 @default.
• W3207591866 cites W2284224350 @default.
• W3207591866 cites W2777270043 @default.
• W3207591866 cites W2806669859 @default.
• W3207591866 cites W2944392111 @default.
• W3207591866 cites W2988342087 @default.
• W3207591866 cites W3017131961 @default.
• W3207591866 cites W3025465714 @default.
• W3207591866 cites W3025691036 @default.
• W3207591866 cites W3092685772 @default.
• W3207591866 cites W3123827820 @default.
• W3207591866 cites W3207548016 @default.
• W3207591866 cites W3207591866 @default.
• W3207591866 cites W4200594888 @default.
• W3207591866 cites W4236676256 @default.
• W3207591866 doi "https://doi.org/10.1111/epi.17092" @default.
• W3207591866 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34633074" @default.
• W3207591866 hasPublicationYear "2021" @default.
• W3207591866 type Work @default.
• W3207591866 sameAs 3207591866 @default.
• W3207591866 citedByCount "21" @default.
• W3207591866 countsByYear W32075918662021 @default.
• W3207591866 countsByYear W32075918662022 @default.
• W3207591866 countsByYear W32075918662023 @default.
• W3207591866 crossrefType "journal-article" @default.
• W3207591866 hasAuthorship W3207591866A5000233437 @default.
• W3207591866 hasAuthorship W3207591866A5004620817 @default.
• W3207591866 hasAuthorship W3207591866A5012220015 @default.
• W3207591866 hasAuthorship W3207591866A5012722318 @default.
• W3207591866 hasAuthorship W3207591866A5016663277 @default.
• W3207591866 hasAuthorship W3207591866A5025122018 @default.
• W3207591866 hasAuthorship W3207591866A5030901765 @default.
• W3207591866 hasAuthorship W3207591866A5052410565 @default.
• W3207591866 hasAuthorship W3207591866A5062520786 @default.
• W3207591866 hasAuthorship W3207591866A5085356343 @default.
• W3207591866 hasBestOaLocation W32075918662 @default.
• W3207591866 hasConcept C118552586 @default.
• W3207591866 hasConcept C126322002 @default.
• W3207591866 hasConcept C197934379 @default.
• W3207591866 hasConcept C2778139780 @default.
• W3207591866 hasConcept C2778186239 @default.
• W3207591866 hasConcept C2778375690 @default.
• W3207591866 hasConcept C2778715236 @default.
• W3207591866 hasConcept C2779384505 @default.
• W3207591866 hasConcept C42219234 @default.
• W3207591866 hasConcept C67761136 @default.
• W3207591866 hasConcept C71924100 @default.
• W3207591866 hasConceptScore W3207591866C118552586 @default.
• W3207591866 hasConceptScore W3207591866C126322002 @default.
• W3207591866 hasConceptScore W3207591866C197934379 @default.
• W3207591866 hasConceptScore W3207591866C2778139780 @default.
• W3207591866 hasConceptScore W3207591866C2778186239 @default.
• W3207591866 hasConceptScore W3207591866C2778375690 @default.
• W3207591866 hasConceptScore W3207591866C2778715236 @default.
• W3207591866 hasConceptScore W3207591866C2779384505 @default.
• W3207591866 hasConceptScore W3207591866C42219234 @default.
• W3207591866 hasConceptScore W3207591866C67761136 @default.
• W3207591866 hasConceptScore W3207591866C71924100 @default.
• W3207591866 hasIssue "12" @default.
• W3207591866 hasLocation W32075918661 @default.
• W3207591866 hasLocation W32075918662 @default.
• W3207591866 hasLocation W32075918663 @default.
• W3207591866 hasOpenAccess W3207591866 @default.
• W3207591866 hasPrimaryLocation W32075918661 @default.
• W3207591866 hasRelatedWork W2022927468 @default.
• W3207591866 hasRelatedWork W2028263964 @default.
• W3207591866 hasRelatedWork W2041350175 @default.
• W3207591866 hasRelatedWork W2159544592 @default.
• W3207591866 hasRelatedWork W2569416438 @default.

• next